Integra LifeSciences (NASDAQ:IART) Issues Q1 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its first quarter 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.400-0.450 for the period, compared to the consensus EPS estimate of 0.560. The company issued revenue guidance of $375.0 million-$385.0 million, compared to the consensus revenue estimate of $411.7 million. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Integra LifeSciences Stock Up 12.1 %

Integra LifeSciences stock opened at $24.72 on Wednesday. The company has a market capitalization of $1.91 billion, a P/E ratio of -274.64, a PEG ratio of 0.73 and a beta of 1.17. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $44.91. The stock has a 50-day simple moving average of $23.71 and a 200-day simple moving average of $21.83.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. During the same quarter in the prior year, the firm earned $0.89 EPS. Integra LifeSciences’s revenue for the quarter was up 11.5% on a year-over-year basis. Equities research analysts expect that Integra LifeSciences will post 2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

IART has been the subject of several recent research reports. Citigroup increased their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Morgan Stanley began coverage on Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price target on the stock. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $23.00.

Insider Transactions at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the transaction, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 3.10% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.